NC
STRO icon

Nexthera Capital’s Sutro Biopharma STRO Stock Holding History

Nexthera Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,950
Closed -$2.25M – 28
2018
Q4 		$2.25M Buy
24,950
+1,789
+8% +$216K 0.93% 18
2018
Q3 		$3.47M Buy
+23,161
New +$3.5M 0.67% 31

Other funds holding STRO

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Nexthera Capital's STRO Position: Q1 2019 in Review

Nexthera Capital sold out of Sutro Biopharma (STRO) in Q1 2019, closing a stake of 24,950 shares — an estimated $2.25M sold.

Nexthera Capital first reported a position in STRO in Q3 2018 and held it in 2 quarters. The position peaked at $3.47M in Q3 2018. 49 funds tracked by Wall St. Rank hold STRO as of Q1 2019.

  • Nexthera Capital reported no remaining Sutro Biopharma position as of Q1 2019 after selling out during the quarter.
  • Nexthera Capital sold 24,950 Sutro Biopharma shares in Q1 2019, an estimated $2.25M.
  • Nexthera Capital first reported a position in Sutro Biopharma in Q3 2018 and held it in 2 quarters.
  • Nexthera Capital's Sutro Biopharma position peaked at $3.47M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2019.

Based on Nexthera Capital's 13F filing for Q1 2019, filed 15 May 2019.